Sage Therapeutics, Inc.
SAGE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 125.1% | 9.7% | 8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100.2% | 95.3% | 88.4% | 55.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -170.9% | -479.7% | -625.9% | -850.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -156.8% | -442.4% | -747.3% | -788.1% |
| EPS Diluted | -0.79 | -1.01 | -1.57 | -1.53 |
| % Growth | 21.8% | 35.7% | -2.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |